Friday, December 13, 2013
CRO Charles River Laboratories International has appointed Craig B. Thompson, M.D., president and CEO, Memorial Sloan-Kettering Cancer Center, to its board of directors. Thompson’s experience with both global pharmaceutical companies and academic institutions in cancer biology and immunology will provide Charles River with a unique combination of experience.
Proteostasis Therapeutics, developing novel therapeutics that regulate protein homeostasis aimed at helping to improve outcomes for patients with orphan and neurodegenerative diseases, has entered into a worldwide collaboration with Biogen Idec to research and develop therapeutic candidates based on the inhibition of Usp14.
The Jain Foundation, a nonprofit organization whose mission is to cure muscular dystrophies caused by dysferlin protein deficiency, has signed a Master Service Agreement with Cellular Dynamics International (CDI), a developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration.
The Biomedical Research Alliance of New York (BRANY), a national organization providing expedited end-to-end solutions for clinical trials support to sponsors and investigators, and the nonprofit Alliance for Clinical Research Excellence and Safety (ACRES), have announced a strategic alliance.
Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, has partnered with LabLogic Systems, an instrument and software provider supporting PET/nuclear medicine facilities, pharmaceutical companies, agrochemical research, universities and CROs, to integrate Certara’s Phoenix WinNonlin pharmacokinetic (PK)/pharmacodynamic (PD) modeling and non-compartmental analysis product with LabLogic’s Debra Laboratory Information Management System (LIMS).
Johnson & Johnson Innovation is collaborating with two Canadian early-stage drug technology development centers to identify and advance biopharmaceutical technologies: Montreal-based NEOMED, a nonprofit, public-private pharma alliance dedicated to drug discovery and development; and Toronto-based MaRS Innovation, the commercialization agent for Ontario’s discovery pipeline from 16 academic institutions,
CRO Algorithme Pharma has partnered with Hôpital Maisonneuve-Rosemont (HMR). The HMR clinical research team includes over 60 clinicians and is supported by 75 employees and 75 graduate students and postgraduates. Together, they form an experienced network working in hematology, oncology, nephrology, ophthalmology and metabolic diseases.